Sandu Pharmaceuticals Ltd
Incorporated in 1985, Sandu Pharmaceuticals
Ltd is a manufacturer of Ayurvedic Medicines.[1]
- Market Cap ₹ 33.9 Cr.
- Current Price ₹ 35.1
- High / Low ₹ 50.0 / 30.0
- Stock P/E 21.9
- Book Value ₹ 43.5
- Dividend Yield 2.85 %
- ROCE 5.47 %
- ROE 3.75 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.81 times its book value
- Company has been maintaining a healthy dividend payout of 34.3%
Cons
- Promoter holding is low: 37.8%
- Company has a low return on equity of 3.80% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.12%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 65.50 | 65.35 | 67.28 | 67.19 | |
| 62.62 | 62.87 | 64.98 | 64.43 | |
| Operating Profit | 2.88 | 2.48 | 2.30 | 2.76 |
| OPM % | 4.40% | 3.79% | 3.42% | 4.11% |
| 0.08 | 0.33 | 0.42 | 0.17 | |
| Interest | 0.11 | 0.08 | 0.06 | 0.10 |
| Depreciation | 0.53 | 0.52 | 0.58 | 0.67 |
| Profit before tax | 2.32 | 2.21 | 2.08 | 2.16 |
| Tax % | 31.47% | 31.22% | 29.33% | 28.24% |
| 1.59 | 1.52 | 1.46 | 1.55 | |
| EPS in Rs | 1.80 | 1.57 | 1.51 | 1.60 |
| Dividend Payout % | 41.56% | 0.00% | 52.93% | 49.86% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -1% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -7% |
| 3 Years: | -22% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| Last Year: | 4% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 8.81 | 9.66 | 9.66 | 9.66 |
| Reserves | 27.66 | 29.58 | 30.93 | 32.36 |
| 0.00 | 0.00 | 0.00 | 0.00 | |
| 12.81 | 14.93 | 11.82 | 13.71 | |
| Total Liabilities | 49.28 | 54.17 | 52.41 | 55.73 |
| 16.00 | 16.62 | 17.88 | 18.15 | |
| CWIP | 0.48 | 0.42 | 0.00 | 0.00 |
| Investments | 9.11 | 9.65 | 10.42 | 11.22 |
| 23.69 | 27.48 | 24.11 | 26.36 | |
| Total Assets | 49.28 | 54.17 | 52.41 | 55.73 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.95 | 0.22 | 0.76 | 0.95 | |
| -5.47 | 0.54 | -1.31 | -0.19 | |
| 0.93 | 0.58 | -0.72 | -0.46 | |
| Net Cash Flow | -3.59 | 1.34 | -1.27 | 0.30 |
| Free Cash Flow | 0.11 | -0.85 | -0.67 | 0.01 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 64% | 37% | 55% | 55% |
Ratios
Consolidated / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 22.23 | 26.75 | 26.42 | 25.86 |
| Inventory Days | 115.06 | 167.70 | 137.28 | 160.90 |
| Days Payable | 69.63 | 98.30 | 47.07 | 51.05 |
| Cash Conversion Cycle | 67.67 | 96.15 | 116.63 | 135.70 |
| Working Capital Days | 42.41 | 52.33 | 56.75 | 62.80 |
| ROCE % | 6.05% | 5.36% | 5.47% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diesel consumption litres ・Standalone data |
|
||||||||||
| Electricity purchased units ・Standalone data |
|||||||||||
| Furnace oil/LSHS consumption litres ・Standalone data |
|||||||||||
| Number of permanent employees employees ・Standalone data |
|||||||||||
| Number of product types products ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Intimation Regarding Change In Name Of Director From Dr Neeti Madan Kapre To Dr Neeti Gupta.
- Director Dr Neeti Madan Kapre’s name changed to Dr Neeti Gupta after marriage.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Compliance certificate under Reg 74(5) of SEBI(DP) Regulation for Q ended 30th September 2026
-
Intimation To The Holders Of Physical Securities To Furnish PAN And KYC Details
- Reminder dated 26 Sep 2026 for physical shareholders to update PAN and KYC details.
- Closure of Trading Window
-
Announcement under Regulation 30 (LODR)-Change in Directorate
- AGM approved Balram Viswanathan's redesignation as Chairman and Managing Director for 3 years, plus Neeti Kapre's 5-year independent directorship.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
SPL is engaged in the business of manufacturing and trading of Ayurveda based medicines under the brand name SANDU